PDF(Pubmed)
Abstract：
Flavonoids seem to have hormone-like and anti-hormone properties so that the consumption of flavonoids may have potential effects on hormone-related cancers (HRCs), but the findings have been inconsistent so far. This meta-analysis was aimed to explore the association between flavonoids intake and HRCs risk among observational studies.
Qualified articles, published on PubMed, EMBASE, and China National Knowledge Infrastructure (CNKI) from January 1999 to March 2022 and focused on relationships between flavonoids (total, subclass of and individual flavonoids) and HRCs (breast, ovarian, endometrial, thyroid, prostate and testicular cancer), were retrieved for pooled analysis. Random effects models were performed to calculate the pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Funnel plots and Begg\'s/Egger\'s test were used to evaluate the publication bias. Subgroup analyses and sensitivity analyses were conducted to explore the origins of heterogeneity.
All included studies were rated as medium or high quality. Higher consumption of flavonols (OR = 0.85, 95% CI: 0.76-0.94), flavones (OR = 0.85, 95% CI: 0.77-0.95) and isoflavones (OR = 0.87, 95% CI: 0.82-0.92) was associated with a decreased risk of women-specific cancers (breast, ovarian and endometrial cancer), while the higher intake of total flavonoids was linked to a significantly elevated risk of prostate cancer (OR = 1.11, 95% CI: 1.02-1.21). A little evidence implied that thyroid cancer risk was augmented with the higher intake of flavones (OR = 1.24, 95% CI: 1.03-1.50) and flavanones (OR = 1.31, 95% CI: 1.09-1.57).
The present study suggests evidence that intake of total flavonoids, flavonols, flavones, flavanones, flavan-3-ols and isoflavones would be associated with a lower or higher risk of HRCs, which perhaps provides guidance for diet guidelines to a certain extent.
This protocol has been registered on PROSPERO with registration number CRD42020200720 .
Qualified articles, published on PubMed, EMBASE, and China National Knowledge Infrastructure (CNKI) from January 1999 to March 2022 and focused on relationships between flavonoids (total, subclass of and individual flavonoids) and HRCs (breast, ovarian, endometrial, thyroid, prostate and testicular cancer), were retrieved for pooled analysis. Random effects models were performed to calculate the pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Funnel plots and Begg\'s/Egger\'s test were used to evaluate the publication bias. Subgroup analyses and sensitivity analyses were conducted to explore the origins of heterogeneity.
All included studies were rated as medium or high quality. Higher consumption of flavonols (OR = 0.85, 95% CI: 0.76-0.94), flavones (OR = 0.85, 95% CI: 0.77-0.95) and isoflavones (OR = 0.87, 95% CI: 0.82-0.92) was associated with a decreased risk of women-specific cancers (breast, ovarian and endometrial cancer), while the higher intake of total flavonoids was linked to a significantly elevated risk of prostate cancer (OR = 1.11, 95% CI: 1.02-1.21). A little evidence implied that thyroid cancer risk was augmented with the higher intake of flavones (OR = 1.24, 95% CI: 1.03-1.50) and flavanones (OR = 1.31, 95% CI: 1.09-1.57).
The present study suggests evidence that intake of total flavonoids, flavonols, flavones, flavanones, flavan-3-ols and isoflavones would be associated with a lower or higher risk of HRCs, which perhaps provides guidance for diet guidelines to a certain extent.
This protocol has been registered on PROSPERO with registration number CRD42020200720 .
摘要：
黄酮类化合物似乎具有激素样和抗激素特性，因此黄酮类化合物的消耗可能对激素相关癌症（HRCs）产生潜在影响。但是到目前为止，调查结果并不一致。这项荟萃分析旨在探讨观察性研究中类黄酮摄入量与HRCs风险之间的关系。
合格的文章，发表在PubMed上,EMBASE,和中国国家知识基础设施(CNKI)，1999年1月至2022年3月，重点研究了黄酮类化合物(总计，类黄酮的亚类和个体类黄酮)和HRCs(乳腺，卵巢,子宫内膜,甲状腺，前列腺癌和睾丸癌)，进行汇总分析。进行随机效应模型以计算合并比值比(OR)和相应的95%置信区间(CI)。漏斗图和Begg/Egger检验用于评估发表偏倚。进行亚组分析和敏感性分析以探索异质性的起源。
所有纳入的研究均被评为中等或高质量。黄酮醇的消费量较高（OR=0.85，95%CI：0.76-0.94），黄酮（OR=0.85，95％CI：0.77-0.95）和异黄酮（OR=0.87，95％CI：0.82-0.92）与女性特异性癌症（乳腺癌，卵巢癌和子宫内膜癌），而总黄酮摄入量较高与前列腺癌风险显著升高相关(OR=1.11,95%CI:1.02-1.21).少量证据表明，黄酮（OR=1.24，95％CI：1.03-1.50）和黄酮（OR=1.31，95％CI：1.09-1.57）的摄入量增加了甲状腺癌的风险。
本研究表明，摄入总黄酮，黄酮醇，黄酮,黄烷酮,黄烷-3-醇和异黄酮与较低或较高的HRCs风险相关，这也许在一定程度上为饮食指南提供了指导。
此协议已在PROSPERO上注册，注册号为CRD42020200720。
合格的文章，发表在PubMed上,EMBASE,和中国国家知识基础设施(CNKI)，1999年1月至2022年3月，重点研究了黄酮类化合物(总计，类黄酮的亚类和个体类黄酮)和HRCs(乳腺，卵巢,子宫内膜,甲状腺，前列腺癌和睾丸癌)，进行汇总分析。进行随机效应模型以计算合并比值比(OR)和相应的95%置信区间(CI)。漏斗图和Begg/Egger检验用于评估发表偏倚。进行亚组分析和敏感性分析以探索异质性的起源。
所有纳入的研究均被评为中等或高质量。黄酮醇的消费量较高（OR=0.85，95%CI：0.76-0.94），黄酮（OR=0.85，95％CI：0.77-0.95）和异黄酮（OR=0.87，95％CI：0.82-0.92）与女性特异性癌症（乳腺癌，卵巢癌和子宫内膜癌），而总黄酮摄入量较高与前列腺癌风险显著升高相关(OR=1.11,95%CI:1.02-1.21).少量证据表明，黄酮（OR=1.24，95％CI：1.03-1.50）和黄酮（OR=1.31，95％CI：1.09-1.57）的摄入量增加了甲状腺癌的风险。
本研究表明，摄入总黄酮，黄酮醇，黄酮,黄烷酮,黄烷-3-醇和异黄酮与较低或较高的HRCs风险相关，这也许在一定程度上为饮食指南提供了指导。
此协议已在PROSPERO上注册，注册号为CRD42020200720。
